I. GOAL

The goal of this REMS is to inform patients about the serious risks associated with the use of testosterone gel.

II. REMS ELEMENTS

A. Medication Guide

A Medication Guide will be dispensed with each testosterone gel prescription in accordance with 21 CFR 208.24.

The Medication Guides are part of the REMS.

B. Timetable for Submission of Assessments

Endo will submit REMS assessments to FDA for testosterone gel by 18 months, 3 years and 7 years from the date of the initial approval (12/2010) of the FORTESTA (testosterone) Gel REMS.

To facilitate inclusion of as much information as possible, while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment. Endo will submit each assessment so that it will be received by FDA on or before the due date.